Live
- Mohanlal and Mammootty unites after two decades
- ‘Sankranthiki Vasthunnam’ locks release date
- How Individuals Can Contribute to Environmental Conservation Efforts and Make a Difference
- Smart Logistics: Leveraging AI for Real-Time Decision Making and Route Optimization
- ‘Bachhala Malli’ set for Dec 20 release
- ‘Devaki Nandana Vasudeva’ creates buzz
- My role in ‘Mechanic Rocky’ will be very unique: Shraddha Srinath
- Bhagyashi Borse comes onboard for ‘RAPO22’
- BGT 2024-25: Yash Dayal added to Indian team’s pace bowling reserve list after Khaleel Ahmed gets injured
- Centre urges southern states to fast-track schemes to boost farm sector
Corona death rate is 6 times lower in countries that use century-old tuberculosis BCG vaccine
London: Countries that have a widespread vaccination programme involving the Bacillus Calmette-Guérin (BCG) jab have a coronavirus death rate almost...
London: Countries that have a widespread vaccination programme involving the Bacillus Calmette-Guérin (BCG) jab have a coronavirus death rate almost six times lower than nations that do not use it, a study reveals.
The BCG vaccine was invented a century ago and gives immunity to tuberculosis (TB) — a bacterial infection — but it is known to have other benefits.
Previous trials discovered people that receive the jab, which costs as little as £30, have improved immune systems and are able to protect themselves from infection.
For example, in a trial among Native Americans, BCG vaccination in childhood was able to offer protection against TB up to 60 years after vaccination.
The precise way this durable vaccine helps fend off other infections is relatively unknown but it may be by boosting the immune system's innate mechanisms.
These so-called off-target effects include enhanced protection against respiratory diseases, and have been recognised by the World Health Organization (WHO).
In the UK, all schoolchildren between ten and 14 were injected with the vaccine between 1953 and 2005.
As TB infection rates dropped, doctors abandoned mass vaccination and, in 2005, switched to targeting only the most at risk — such as babies with infected relatives.
Researchers hope it will turbo-charge the immune system so that it is in a heightened state of readiness and able to detect and destroy the virus before it wreaks havoc on the body.
The researchers adjusted for factors which can skew the findings, such as a nation's wealth and the percentage of elderly people in its population.
They then looked at the mortality per one million residents of every country with sufficient data.
Researchers from the US write in their paper: 'After adjusting for country economic status, proportion of older population and aligning the epidemic trajectories of the highest hit countries, the intriguing observation of a significant association between BCG use and lower COVID-19-attributable mortality remained discernable.'
